Renerve LimitedASX: RNV

Positive 12-Month Data for NervAlign Nerve Guide Matrix

· Issued by Renerve Limited via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

The study showed that animals treated with the NervAlign matrix exhibited similar walking ability and nerve function recovery compared to those treated with an autologous nerve graft. Preliminary analysis indicated successful regrowth of blood vessels and nerve fibers, with further assessments planned for additional animals. The company is optimistic about these results, which suggest that the NervAlign matrix could serve as a viable alternative to traditional nerve grafting techniques.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

+61 (03) 9482 3940 157 Heidelberg Rd, Northcote, VIC 3070 www.renerve.com.au ASX Announcement 19 October 2026 Positive 12-month preclinical data for NervAlign® Nerve Guide Matrix Key Highlights • 12-month preclinical sheep data show strong nerve regeneration and return of nerve function across...

Renerve Limited on 6ix

Story so far

Earlier from Renerve

All Renerve news releases